Schonfeld Strategic Advisors LLC Cuts Position in NeoGenomics, Inc. (NASDAQ:NEO)

Schonfeld Strategic Advisors LLC lessened its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 76.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,280 shares of the medical research company's stock after selling 54,330 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in NeoGenomics were worth $268,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. First Light Asset Management LLC boosted its holdings in shares of NeoGenomics by 3.0% during the 4th quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock valued at $52,202,000 after acquiring an additional 91,030 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of NeoGenomics by 7.4% during the 4th quarter. Northern Trust Corp now owns 1,621,809 shares of the medical research company's stock valued at $26,727,000 after acquiring an additional 111,170 shares in the last quarter. Oberweis Asset Management Inc. boosted its holdings in shares of NeoGenomics by 7.0% during the 4th quarter. Oberweis Asset Management Inc. now owns 768,700 shares of the medical research company's stock valued at $12,668,000 after acquiring an additional 50,000 shares in the last quarter. Greenhouse Funds LLLP boosted its holdings in shares of NeoGenomics by 5.3% during the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock valued at $77,487,000 after acquiring an additional 237,491 shares in the last quarter. Finally, Mirova acquired a new stake in shares of NeoGenomics during the 4th quarter valued at $1,070,000. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Stock Up 3.4%

Shares of NEO traded up $0.27 during trading hours on Friday, hitting $8.11. The stock had a trading volume of 1,257,184 shares, compared to its average volume of 1,127,511. The firm has a market capitalization of $1.04 billion, a P/E ratio of -13.08 and a beta of 1.60. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. NeoGenomics, Inc. has a 1-year low of $6.08 and a 1-year high of $19.12. The firm has a 50 day simple moving average of $9.01 and a 200-day simple moving average of $12.89.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The company had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. NeoGenomics's revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.02) EPS. Sell-side analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling at NeoGenomics

In related news, Director Lynn A. Tetrault purchased 7,000 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were bought at an average price of $8.14 per share, with a total value of $56,980.00. Following the acquisition, the director now owns 7,000 shares of the company's stock, valued at $56,980. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Warren Stone purchased 5,700 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average cost of $8.58 per share, for a total transaction of $48,906.00. Following the acquisition, the chief operating officer now directly owns 108,280 shares in the company, valued at $929,042.40. This trade represents a 5.56% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 65,600 shares of company stock worth $512,438. Insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NEO. StockNews.com raised NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday, May 13th. The Goldman Sachs Group lowered their target price on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Piper Sandler set a $12.00 target price on NeoGenomics and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Guggenheim initiated coverage on NeoGenomics in a research report on Thursday. They set a "neutral" rating for the company. Finally, Bank of America lowered their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $13.83.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.